scholarly journals Retrospective Analysis of Clinical Outcomes in Patients with Immunoglobulin A Nephropathy and Persistent Hematuria Following Renin-Angiotensin System Blockade

2020 ◽  
Vol 26 ◽  
Author(s):  
Jingjing Chen ◽  
Shao Liu ◽  
Hui Xu ◽  
Wei Wang ◽  
Yanyun Xie ◽  
...  
Keyword(s):  
Retrospective Analysis ◽  
Clinical Outcomes ◽  
Immunoglobulin A ◽  
Renin Angiotensin System ◽  
Immunoglobulin A Nephropathy ◽  
Angiotensin System ◽  
Renin Angiotensin

scholarly journals Impact of Treatment with Renin–Angiotensin System Inhibitors on Clinical Outcomes in Hypertensive Patients Hospitalized with COVID-19

2020 ◽  
Vol 27 (6) ◽  
pp. 561-568 ◽  
Author(s):  
Martin Negreira-Caamaño ◽  
Jesus Piqueras-Flores ◽  
Jorge Martínez-DelRio ◽  
Patricia Nieto-Sandoval-Martin-DeLaSierra ◽  
Daniel Aguila-Gordo ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Renin Angiotensin System ◽  
Angiotensin System ◽  
Hypertensive Patients ◽  
Renin Angiotensin

scholarly journals Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure

2014 ◽  
Vol 35 (26) ◽  
pp. 1760-1768 ◽  
Author(s):  
Emmanuel Sorbets ◽  
Julien Labreuche ◽  
Tabassome Simon ◽  
Laurent Delorme ◽  
Nicolas Danchin ◽  
...  
Keyword(s):  
Heart Failure ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Clinical Outcomes ◽  
Stable Coronary Artery Disease ◽  
Renin Angiotensin System ◽  
Angiotensin System ◽  
Renin Angiotensin ◽  
Artery Disease

scholarly journals Comparative analysis between the use of renin–angiotensin system antagonists and clinical outcomes of hospitalized patients with COVID-19 respiratory infection

2020 ◽  
Vol 155 (11) ◽  
pp. 473-481 ◽  
Author(s):  
Jorge Martínez-del Río ◽  
Jesús Piqueras-Flores ◽  
Patricia Nieto-Sandoval Martín de la Sierra ◽  
Martín Negreira-Caamaño ◽  
Daniel Águila-Gordo ◽  
...  
Keyword(s):  
Comparative Analysis ◽  
Clinical Outcomes ◽  
Respiratory Infection ◽  
Renin Angiotensin System ◽  
Hospitalized Patients ◽  
Angiotensin System ◽  
Renin Angiotensin

scholarly journals The effectiveness and safety of full-dose versus half-dose corticosteroid plus renin-angiotensin system blockers for IgA nephropathy

2019 ◽  
Vol 10 ◽  
pp. 204062231988787
Author(s):  
Li Wang ◽  
Daijin Ren ◽  
Tianlun Huang ◽  
Xin Liu ◽  
Gaosi Xu
Keyword(s):  
Complete Remission ◽  
Immunoglobulin A ◽  
Renin Angiotensin System ◽  
Angiotensin System ◽  
Full Dose ◽  
Renin Angiotensin ◽  
Half Dose ◽  
Remission Rates ◽  
Dose Corticosteroid ◽  
Renin Angiotensin System Blockers

Background: Observational studies suggest that patients with immunoglobulin A nephropathy (IgAN) showed good responses to corticosteroids (CS) but experienced severe adverse effects. The authors conducted a cohort study to evaluate the effectiveness and safety of half-dose CS plus renin-angiotensin system blockers (RASB) (CS + RASB) versus full-dose CS in IgAN patients. Methods: A total of 162 kidney biopsy-confirmed IgAN patients with protein excretion levels ⩾0.75 g/d and an estimated glomerular filtration rate (eGFR) >30 ml/min/1.73 m2 were included. A total of 89 patients received half-dose CS + RASB (half CS + RASB), and 73 patients received full-dose CS (full CS). The primary outcomes were the complete remission rates and incidence of adverse events (AEs). The secondary outcomes included 24 h urinary protein (UP) levels and a combined event. Results: Over the 18 months follow-up, the complete remission rates were 59% (53/89 patients) and 57% (42/73 patients) in the half CS + RASB and full CS groups ( p = 0.88), respectively. A total of five patients suffered from serious AEs (SAEs) in the full CS group during the observation period, and no SAEs were observed in the half CS + RASB group ( p = 0.012). The incidences of total AEs ( p = 0.003) and infections ( p = 0.01) were lower in the half CS + RASB group than in the full CS group. Conclusions: Although half CS + RASB versus full CS did not differ in terms of reducing proteinuria, therapy with half CS + RASB resulted in fewer AEs in the IgAN patients.

scholarly journals Peripheral Levels of Renin-Angiotensin System Components Are Associated With Cognitive Performance in Huntington’s Disease

2020 ◽  
Vol 14 ◽  
Author(s):  
Natalia P. Rocha ◽  
Courtney Cleary ◽  
Gabriela D. Colpo ◽  
Erin Furr Stimming ◽  
Antonio L. Teixeira
Keyword(s):  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Clinical Outcomes ◽  
Plasma Concentrations ◽  
Renin Angiotensin System ◽  
Enzyme Linked Immunosorbent Assay ◽  
Ang Ii ◽  
Significant Group ◽  
Angiotensin System ◽  
Renin Angiotensin

The renin-angiotensin system (RAS) has proven to be involved in the pathophysiology of neurodegenerative diseases, such as Parkinson’s disease (PD) and Alzheimer’s disease (AD), serving as a potential therapeutic target and a disease burden marker. Studies have associated negative clinical outcomes with the activation of the classical RAS arm composed of the angiotensin-converting enzyme (ACE) and angiotensin (Ang) II, while suggested positive outcomes with the activation of the counter-regulatory RAS arm involving ACE2 and Ang-(1–7). Huntington’s disease (HD) shares many pathological and clinical outcomes with AD and PD, but the evidence of direct involvement of RAS components in the pathophysiology of HD is still limited and needs further investigation. Herein, we investigated peripheral levels of the RAS components Ang II, Ang-(1–7), ACE, and ACE2 in controls, premanifest, and manifest HD gene carriers and their relationship with clinical outcomes. Peripheral blood samples were collected via phlebotomy, and plasma concentrations of RAS components were measured by Enzyme-Linked Immunosorbent Assay. Clinical evaluation included a questionnaire about socio-demographic characteristics, motor, and cognitive assessments. Results showed (1) no significant group differences in plasma concentrations of RAS components; (2) positive correlations between ACE2 and Verbal Fluency Test (VFT) scores; and (3) negative correlations between Ang II and Mini–Mental State Examination scores. These results corroborate the proposed balance between the classical (ACE/Ang II) and the counter-regulatory [ACE2/Ang-(1–7)] arms of the RAS, with the former associated with negative clinical outcomes and the latter with positive effects in HD.

Sign in / Sign up

Export Citation Format

Share Document